Although pemafibrate, a selective peroxisome proliferator‐activated receptor α (PPARα) modulator primarily prescribed for hypertriglyceridemia, may improve liver function in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), its efficacy has not been sufficiently evaluated. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.